Advanced Technology Solutions

Lipitor Patent Expiration

Mouthwash with line extensions and packaging improvements. A synopsis of today's Analyst Interview is presented below. Pfizer has stopped selling Bextra after an order from the Food and Drug Administration in April 2005; but it continues to market Celebrex, albeit now with a "black box" warning label of possible cardiovascular and gastrointestinal risks. Pfizer had been counting on torcetrapib to make up for several patent Lipitor patent expiration expirations, including one on cholesterol-lowering Lipitor, Pfizer's top-selling product with $12 billion in annual sales. Pfizer is hoping this compound will come to the rescue of its $12 billion-seller Lipitor, lipitor patent expiration when its patent expires in 2010. It is lipitor patent expiration the first new prescription treatment for schizophrenia to be approved by the FDA since 2003. Lipitor is sold in Germany under the Lipitor patent expiration brand name Sortis. With 63 million Americans now estimated to have dyslipidemia and 47 million lipitor patent expiration with hypertension, some 30 million Americans shake out as at risk for both high cholesterol and high blood pressure. Already, the company has an advertorial that's been placed in a number lipitor patent expiration of cardiology journals, Holmes said. Acquisitions will lipitor patent expiration help, too.
Physicians are not Lipitor patent expiration necessarily targeting this patient population.
Approved in February, Caduet will be available this spring in multiple dosage combinations. In particular, the group would focus on its core research and development, manufacturing Lipitor patent expiration and commercial operations. As 2005 saw a decline in the number of NCEs approved down to 18 from 23 in 2004, there is clear evidence that the loss of revenue from patent-protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market. And Moody's Investors Service slashed the company's triple-A rating to Aa2, anticipating costs of litigation that could exceed $10 billion. We think ETC-2f6 could be Pfizer's ticket to continued robust earnings growth after its Lipitor patents expire in 2006, S&P stated. Steven Nissen, who led one recent study of torcetrapib, will present results of other studies on the Pfizer drug that may shed light on whether it was uniquely dangerous. The decision -- which resulted from a patent challenge by generic manufacturers Ranbaxy Laboratories Limited and Basics GmbH -- has no immediate commercial impact because neither company has regulatory approval to sell a generic atorvastatin product in Germany, and because Pfizer's basic patent covering atorvastatin remains in force, and expires after the enantiomer patent.